Efficacy and Safety of "Jiedu Tongluo Therapy" for Diabetic Kidney Disease： A Systematic Review and Meta-analysis
10.13422/j.cnki.syfjx.20230818
- VernacularTitle:解毒通络法治疗糖尿病肾病有效性及安全性的Meta分析
- Author:
Yuxin LIU
1
;
Xiaoling SHANG
1
;
Hongliang WU
2
Author Information
1. School of Basic Medical Sciences， Changchun University of Chinese Medicine， Changchun 130117，China
2. Jilin Provincial Institute of Education，Changchun 130022，China
- Publication Type:Journal Article
- Keywords:
diabetic kidney disease， Jiedu Tongluo therapy;
traditional Chinese medicine;
traditional Chinese and western medicine;
Meta-analysis
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(21):165-171
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo systematically evaluate the efficacy and safety of Jiedu Tongluo therapy in the treatment of diabetic kidney disease （DKD）. MethodDatabases including CNKI， Wanfang Data， PubMed， and Web of Science were systematically searched from January 2003 to December 2022 for clinical randomized controlled trials （RCTs） on the application of Jiedu Tongluo therapy for DKD treatment over the past 20 years. In these trials， the control group received conventional treatment （including diabetes and kidney health education， glycemic and blood pressure control， and lifestyle interventions）， along with western medicine or Chinese patent medicine treatment. The experimental group received primarily Jiedu Tongluo therapy via oral administration of Chinese medicine or in combination with western medicine. The Cochrane risk of bias assessment tool was used for the quality evaluation of the trials， and R 4.1.0 statistical software was used for analysis. ResultForty-one RCTs with 3 478 participants were included. The Meta-analysis results demonstrated that the experimental group， compared with the control group， showed significant improvement in overall clinical efficacy ［odds ratio （OR）=2.46， 95% confidence interval （CI） （2.08， 2.92）， I2=0%］， effective reduction of serum creatinine （Scr） levels ［mean difference （MD）=-15.83， 95% CI （-21.5， -10.37）， P< 0.01］， 24-hour urinary protein excretion rate （24 h-Up） ［MD=-350.88， 95% CI （-419.49， -282.28）， P< 0.01］， TCM syndrome score ［MD=-6.08， 95% CI （-7.81， -4.36）， P<0.01］， and effective regulation of fasting blood glucose （FBG） ［MD=-0.57， 95% CI （-0.75， -0.38）， P<0.01］. The treatment also demonstrated certain safety ［OR=0.99， 95% CI （0.35， 2.76）］. ConclusionJiedu Tongluo therapy in DKD treatment exhibits favorable clinical efficacy and safety. However， due to limitations in the quality and quantity of the included literature， these conclusions should be further validated through larger-scale， high-quality RCTs.
